Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy's 2018 impact factor is 8.402. Molecular Therapy — Methods & Clinical Developments The aim of Molecular Therapy—Methods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella. Molecular Therapy – Methods & Clinical Development's 2018 impact factor is 4.875. Topics of particular interest within the journal's scope include: Gene vector engineering and production Methods for targeted genome editing and engineering Methods and technology development for cell reprogramming and directed differentiation of pluripotent cells Methods for gene and cell vector delivery Development of biomaterials and nanoparticles for applications in gene and cell therapy and regenerative medicine Analysis of gene and cell vector biodistribution and tracking Pharmacology/toxicology studies of new and next-generation vectors Methods for cell isolation, engineering, culture, expansion, and transplantation Cell processing, storage, and banking for therapeutic application Preclinical and QC/QA assay development Translational and clinical scale-up and Good Manufacturing procedures and process development Clinical protocol development Computational and bioinformatic methods for analysis, modeling, or visualization of biological data Negotiating the regulatory approval process and obtaining such approval for clinical trials

《分子疗法》 是有关基因转移，载体开发和设计，干细胞操作，基于基因，肽，蛋白质，寡核苷酸和基于细胞的疗法的开发领域的领先期刊，以纠正遗传性和后天性疾病，疫苗开发，临床前靶标验证，安全性/功效研究和临床试验。分子疗法 致力于促进遗传学，医学和生物技术领域的科学发展。该刊发表重要的同行评审研究以及前沿的评论和评论，继续吸引该领域的最佳材料。 分子疗法的 2018影响因子是8.402。 分子疗法—方法与临床发展 的目的 分子疗法的方法与临床发展 是建立在成功分子疗法 在出版重要同行评审的方法和程序，以及翻译的进步领域的分子治疗伞下的广泛阵列英寸 分子疗法–方法与临床发展的 2018影响因子是4.875。 在期刊范围内特别感兴趣的主题包括： 基因载体工程与生产 靶向基因组编辑和工程方法 用于多能细胞的细胞重编程和定向分化的方法和技术发展 基因和细胞载体传递的方法 用于基因和细胞疗法以及再生医学的生物材料和纳米颗粒的开发 基因和细胞载体的生物分布和追踪分析 新一代载体的药理/毒理学研究 细胞分离，工程改造，培养，扩增和移植的方法 细胞处理，存储和库存用于治疗应用 临床前和QC / QA分析开发 转化和临床扩大生产以及良好制造程序和过程开发 临床方案开发 用于分析，建模或可视化生物数据的计算和生物信息学方法 谈判监管批准程序并获得临床试验的批准。